Daniel SCOTCHER      SITE

  • Drug Metab Dispos. 2021;In press.  Hepatic scaling factors for in vitro-in vivo extrapolation (IVIVE) of metabolic drug clearance in patients with colorectal cancer with liver metastasis. Vasilogianni AM, Achour B, Scotcher D, Peters SA, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. PubMed
  • Clin Pharmacokinet. 2021;In press.  Clinical investigation on endogenous biomarkers to predict strong OAT-mediated drug-drug interactions. Willemin ME, Van Der Made TK, Pijpers I, Dillen L, Kunze A, Jonkers S, Steemans K, Tuytelaars A, Jacobs F, Monshouwer M, Scotcher D, Rostami-Hodjegan A, Galetin A, Snoeys J. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2020;9:695-706. Physiologically-based pharmacokinetic modelling of Creatinine-drug interactions in the chronic kidney disease population. Takita H, Scotcher D, Chinnadurai R, Kalra PA, Galetin A. PubMed
  • Drug Metab Dispos. 2020;48:1271-1282. Scaling factors for clearance in adult liver cirrhosis. El-Khateeb E, Achour B, Scotcher D, Al-Majdoub ZM, Athwal V, Barber J, Rostami-Hodjegan A. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2020;9:310-321. A novel physiologically based model of Creatinine renal disposition to integrate current Kknowledge of systems parameters and clinical observations. Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang SM, Rostami-Hodjegan A, Galetin A. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2020;9:282-293. Mechanistic models as framework for understanding biomarker disposition: Prediction of Creatinine-drug interactions. Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang SM, Rostami-Hodjegan A, Galetin A. PubMed
  • Mol Pharm. 2019;16:4551-4562. Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated Indoxyl Sulfate secretion in chronic kidney disease. van der Made TK, Fedecostante M, Scotcher D, Rostami-Hodjegan A, Sastre Toraño J, Middel I, Koster AS, Gerritsen KG, Jankowski V, Jankowski J, Hoenderop JGJ, Masereeuw R, Galetin A. PubMed
  • J Pharmacol Exp Ther. 2019;368:157-168. Towards further verification of physiologically-based kidney models: Predictability of the effects of urine-flow and urine-pH on renal clearance. Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A. PubMed
  • Drug Metab Dispos. 2017;45:556-568. Microsomal and cytosolic scaling factors in dog and human kidney cortex and application for in vitro-in vivo extrapolation of renal metabolic clearance. Scotcher D, Billington S, Brown J, Jones CR, Brown CDA, Rostami-Hodjegan A, Galetin A. PubMed
  • J Pharmacol Exp Ther. 2017;360:484-495. Delineating the role of various factors in renal disposition of Digoxin through application of physiologically based kidney model to renal impairment populations. Scotcher D, Jones CR, Galetin A, Rostami-Hodjegan A. PubMed
  • AAPS J. 2016;18:1082-1094.  Key to opening kidney for in vitro-in vivo extrapolation entrance in health and disease: Part II: Mechanistic models and in vitro-in vivo extrapolation. Scotcher D, Jones C, Posada M, Galetin A, Rostami-Hodjegan A. PubMed
  • Eur J Pharm Sci. 2016;94:59-71. Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. Scotcher D, Jones C, Rostami-Hodjegan A, Galetin A. PubMed

PubMed

Manchester (UK)

SCOTCHER DANIEL.jpg

Last update: June 2021